Pharmozyme
Pre-clinicalIntroducing Our UTI qPCR Panel targeting the most common UTI pathogens in the United States.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $37M
About
Introducing Our UTI qPCR Panel targeting the most common UTI pathogens in the United States.
Genetics & Genomics
Funding History
2Total raised:$37M
Series A$32MFeb 15, 2023
Seed$5MJun 15, 2021